Cindy Boer

146 | Chapter 3.2 References 1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseas- es and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018. 392(10159): p. 1789-1858. 2. Hunter, D.J. and S. Bierma-Zeinstra, Osteoarthritis. Lancet, 2019. 393(10182): p. 1745-1759. 3. Neogi, T., et al., Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthri- tis Rheum, 2006. 54(4): p. 1255-61. 4. Misra, D., et al., Vitamin K deficiency is associated with incident knee osteoarthritis. Am J Med, 2013. 126(3): p. 243-8. 5. Shea, M.K., et al., The association between vitamin K status and knee osteoarthritis features in older adults: the Health, Aging and Body Composition Study. Osteoarthritis Cartilage, 2015. 23(3): p. 370-8. 6. Neogi, T., et al., Vitamin K in hand osteoarthritis: results from a randomised clinical trial. Ann Rheum Dis, 2008. 67(11): p. 1570-3. 7. Yin, T. and T. Miyata, Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1- rationale and perspectives. Thromb Res, 2007. 120(1): p. 1-10. 8. Luo, G., et al., Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA pro- tein. Nature, 1997. 386(6620): p. 78-81. 9. Newman, B., et al., Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival. J Cell Biol, 2001. 154(3): p. 659-66. 10. den Hollander, W., et al., Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand. Ann Rheum Dis, 2017. 76(12): p. 2046-2053. 11. Holbrook, A., et al., Evidence-based management of anticoagulant therapy: Antithrombotic Ther- apy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141(2 Suppl): p. e152S-e184S. 12. Krijthe, B.P., et al., Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J, 2013. 34(35): p. 2746-51. 13. Zhu, J., et al., Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy, 2018. 38(9): p. 907-20. 14. Ikram, M.A., et al., Objectives, design and main findings until 2020 from the Rotterdam Study. Eur J Epidemiol, 2020. 35(5): p. 483-517. 15. Kellgren, J.H. and J.S. Lawrence, Radiological Assessment of Osteo-Arthrosis. Ann Rheum Dis, 1957. 16(4): p. 494-502. 16. Kerkhof, H.J., et al., Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage, 2011. 19(3): p. 254- 64. 17. Odding, E., et al., Association of locomotor complaints and disability in the Rotterdam study. Ann Rheum Dis, 1995. 54(9): p. 721-5. 18. Clockaerts, S., et al., Statin use is associated with reduced incidence and progression of knee os- teoarthritis in the Rotterdam study. Ann Rheum Dis, 2012. 71(5): p. 642-7. 19. Teichert, M., et al., A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet, 2009. 18(19): p. 3758-68. 20. Whirl-Carrillo, M., et al., Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther, 2012. 92(4): p. 414-7. 21. McCarthy, S., et al., A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet, 2016. 48(10): p. 1279-83. 22. Sinnwell JP, S.D., haplo.stats: Statistical Analysis of Haplotypes with Traits and Covariates when linkag pahs is Ambigous. 2018.